key: cord-0864601-h9qbh9yv
authors: Erster, O.; Mendelson, E.; Levy, V.; Kabat, A.; Mannasse, B.; Asraf, H.; Azar, R.; Ali, Y.; Shirazi, R.; Bucris, E.; Bar-Ilan, D.; Mor, O.; Mandelboim, M.; Sofer, D.; Fleishon, S.; Zukerman, N. S.
title: Rapid And high throughput RT-qPCR assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.351
date: 2021-05-22
journal: nan
DOI: 10.1101/2021.05.19.21257439
sha: 4f141e521fa488646be0144e8182121cf2a3f40d
doc_id: 864601
cord_uid: h9qbh9yv

Emerging SARS-CoV-2 (SC-2) variants with increased infectivity and vaccine resistance are of major concern. Rapid identification of such variants is important for the public health activities and provide valuable data for epidemiological and policy decision making. We developed a multiplex quantitative RT-qPCR (qPCR) assay that can specifically identify and differentiate between the emerging B.1.1.7 and B.1.351 SC-2 variants. In a single assay, we combined four reactions: one that detects SC-2 RNA independently of the strain, one that detects the D3L mutation, which is specific to variant B.1.1.7, and one that detects the 242-244 deletion, which is specific to variant B.1.351. The fourth reaction identifies human RNAseP gene, serving as an endogenous control for RNA extraction integrity. We show that the strain-specific reactions target mutations that are strongly associated with the target variants, and not with other major known variants. The assay specificity was tested against a panel of respiratory pathogens (n=16), showing high specificity towards SC-2 RNA. The assay sensitivity was assessed using both In-vitro transcribed RNA and clinical samples, and was determined to be between 20 and 40 viral RNA copies per reaction. The assay performance was corroborated with Sanger and whole genome sequencing, showing complete agreement with the sequencing results. The new assay is currently implemented in the routine diagnostic work at the Central Virology Laboratory, and may be used in other laboratories to facilitate the diagnosis of these major worldwide circulating SC-2 variants.

The recent emergence of new SARS-COV-2 (SC-2) variants of concern (VOC) B. 1 An additional SC-2 VOC is the B.1.351 variant, which contains both B.1.351-unique mutations and mutations that are present in other notable VOC, such as the SGF deletion in the nsp6 gene, and the N501Y substitution in the spike gene that is identified also in the B1.1.7 (5). Like variant B.1.1.7, this variant was found to be more infectious than the WT strain. In vitro studies also show that it has increased resistance to serum of recovered and vaccinated patients, thereby posing a serious threat on the efficacy of current vaccination campaigns (6) (7) (8) .

The emergence of these two variants, as well as other recently emerging SC-2 strains, necessitates constant improvement of the diagnostic tools used to combat the COVID-19 pandemic. In addition to performing a rapid, sensitive and specific detection of the viral RNA, diagnostic tests are now required to differentiate between circulating strains to provide valuable epidemiological data for policy decision . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) detect specific key mutations. However, recent studies showed that in spite of sharing such mutations, variants might differ in their antibody resistance capacity, prompting development of variant specific assays [5, 9] . These findings highlight the need to determine the identity of circulating strains, not only specific mutations. By designing a multiplex PCR assay that positively detects the presence of unique mutations that are strongly associated with variants B.1.1.7 and B.1.351, rapid, economical high throughput screening can be performed, enabling robust and specific identification of these variants in SC-2 positive clinical samples.

In this report, we describe a differential RT-qPCR assay that detects the presence of mutations strongly associated with variants B.1.1.7 and B.1.351. We demonstrate that implementation of this novel multiplex assay allows a sensitive and specific detection of SC-2 RNA, with the advantage of variant differentiation in a single assay.

Analysis of SC-2 sequences and primer simulations were performed using the Geneious software package (https://www.geneious.com/) and the NCBI BLAST analysis tools (https://blast.ncbi.nlm.nih.gov/). SC-2 sequences were obtained from GISAID initiative website (https://www.gisaid.org/) and Analyzed using the Geneious software. All primer and probe sequences are detailed in Table 1 .

Nasopharyngeal swab samples suspected to contain SC-2 in viral transport media (VTM) were inactivated by heating at 70°C for 30 minutes, or, if intended to be used for culturing, inactivated by addition of 200µl lysis buffer (Zymo research, https://www.zymoresearch.com/products/dna-rna-lysis-buffer ) to 200µl VTM.. Total RNA extraction was performed with either the Roche MagNA pure 96 system (https://lifescience.roche.com/), or the PSS MagLEAD instrument (http://www.pss.co.jp/english/ ). The eluted RNA was stored at -80°C for further use, or used immediately thereafter for the PCR test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

In order to establish the analytical Limit of Detection (LOD) and obtain standard controls for WT and mutant target sequences, genomic regions including the E, S 242 , S RBD , N and RNASE P were amplified using primers that contain the T7 promoter minimal sequence ( Table 2 ) with the MyTaq One-step RT-PCR kit.

The resulting PCR products were transcribed In vitro to RNA using the T7 Megascript kit according to the manufacturer's instructions (Thermo Fisher, https://www.thermofisher.com/). The In-vitro transcribed RNA was purified and its concentration was determined using Nanodrop spectrophotometer and stored at -80°C.

RT-qPCR mix was prepared with the Meridian (formerly Bioline) SensiFast one-step mix (https://www.bioline.com/). Initial optimization was performed by setting an annealing temperature gradient. Following optimization of the reaction conditions, the final mix concentration was determined.

The reaction mix was assembled as follows: SensiFast Probe Lo-ROX One-Step: 12.5µl, E Sarbeco-F1b: Table 2 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.19.21257439 doi: medRxiv preprint Endpoint PCR reactions were performed with MyTaq One-step RT-PCR kit (Meridian, https://www.bioline.com/mytaq-mix.html) according to the manufacturer's instructions. Resulting PCR products were analyzed using agarose gel electrophoresis and sequenced using the ABI 3500 Bioanalyzer.

COVID-seq kit was used for library preparation as per manufacturer's instructions (Illumina, https://www.illumina.com/). Library validation and mean fragment size was determined by TapeStation 4200 via DNA HS D1000 kit (Agilent, https://www.agilent.com/). Libraries were pooled, denatured and diluted to 10pM and sequenced on NovaSeq (Illumina).

Fastq files underwent quality control using FastQC (www.bioinformatics.babraham.ac.uk/ projects/fastqc/) and MultiQC [10] and low-quality sequences were filtered using trimmomatic [PMID: 24695404]. Mapping to SARS-CoV-2 genome (NC_045512.2) was performed with BWA mem [PMID: 19451168] . SAMtools suite [PMID: 19505943] was used to filter unmapped reads, sort and index bam files. Consensus fasta sequences were constructed for each sample using iVar (https://andersenlab.github.io/ivar/html/manualpage.html), with Ns inserted in positions with sequencing depth lower than five. Sequences were aligned with the SARS-CoV-2 reference sequence (NC_045512.2) with MAFFT [11] and mutation analysis was done with a custom R code using Bioconductor package seqinr [citation info in: https://cran.r-project.org/web/packages/seqinr/citation.html]. a.a. substitution. Additionally, there is a single "A" deletion in this region, 5 bases upstream to the N gene start codon (Figure 1) . A selective primer was designed accordingly, to specifically detect the mutated variant. The reverse primer and the probe were based on the CDC N1 reaction (https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html), as detailed in Table 1 . The B.1.1.7-specific reaction was combined with an inclusive reaction based on the E-sarbeco qPCR described by Corman et al. (12) , with minor modifications, as detailed in Table 1 . This reaction was designed to detect all known CoV19 clades, thereby serving as an indicator for the presence of SC-2 RNA in the examined sample. The combined assay was then tested using WT and sequence-verified samples identified as belonging to lineage B.1.1.7 (Figure 1 ). All samples identified as belonging to clade B.1.1.7

were detected using the new multiplex assay. WT samples were either negative for the N reaction, or gave a very weak signal, approximately 10-15 cycles apart from the E reaction signal (Figure 1) . This reaction was termed N gene D3L reaction.

This variant contains two unique mutations in the spike gene, D215G and a deletion at amino acid position 242 (nucleotide positions 22281 and 22289 in sequence NC_045512). A specific reaction was developed, based on these mutations, which detects samples of lineage B.1.351, as described. The forward primer was designed to anneal to the substituted nucleotide at its 3'p end. In order to increase the primer selectivity, a mismatched base was inserted 10 b.p. downstream to the 5'p end. The reverse primer was designed to complement the region of the 242-244 deletion (Figure 2) . This reaction resulted in a negative, or a very weak signal, when testing WT samples, and a clear signal when testing samples previously sequenced and identified as belonging to the B.1.351 clade (Figure 2) . This reaction was then termed S 242 reaction.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The two reactions were combined with the E target reaction and a reaction targeting the RNAse P gene (https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html) that serves as an endogenous control for RNA extraction. The multiplex reaction was then tested for sensitivity using serial dilutions of in vitro-transcribed RNA containing the target sequences of all four reactions. As detailed in Supplementary Figure S3 , the calculated analytical limit of detection for the three viral targets was as follows: 29 copies per reaction for the E-sarbeco reaction, 26 copies per reaction for the N D3L , and 39 copies per reaction for the S 242 reactions. This sensitivity was accomplished using a reaction that takes less than 70 minutes, thereby shortening the entire time from sample to answer.

Specificity test performed with a panel of respiratory pathogens showed no cross-detection of pathogens other than SC-2, except for SARS CoV-1 (SC-1), which was detected, as expected, by the E-sarbeco reaction. Nucleic acid samples of the following pathogens were tested: Chlamydia pneumonia, 

The emergence of new, more contagious and potentially antigenically different SC-2 lineages pose an urgent need to adjust rapid detection methods to meet public health related needs. To meet these needs, we developed a multiplex RT-qPCR assay that can distinguish between three SC-2 lineages. The assay is rapid (~1 hour PCR assay time) and is suitable for high throughput rapid screening. This is in contrast to Sanger sequencing or NGS, which are more informative, but are far more expensive, take significantly more time, and cannot be scaled up easily. Since the beginning of the COVID-19 pandemic, several rapid tests detecting the presence of SC-2 RNA or proteins were implemented in wide scale testing (13) . However, the capacity to distinguish between different lineages in a time scale of hours is currently possible only using qPCR. SC-2 variant B.1.1.7 contains numerous synonymous and non-synonymous mutations, of which the Spike gene mutations 69-70del, N501Y, and P681H received most attention due to their potential effect on virus infectivity (14) (15) . For diagnostic purposes, however, the N501Y mutation is not variant-specific, as it was identified in several variants other than variant B.1.1.7, such as B.1.351 and the P.1 variant first discovered in Brazil (16) . The D3L substitution in the N gene used in our assay is specific to variant B.1.1.7

and was not reported in other major SC-2 lineages. Although this mutation can occur independently from other characteristic mutations, such as N501Y, its presence strongly suggests that the examined sample . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S4) . The combinations of these two reactions therefore provides a reliable tool to identify each of these two variants with high confidence. In order to increase the range of the new assay, the SC-2 inclusive reaction targeting the E gene (12) was combined, thereby enabling detection of the viral RNA independently of the strain examined.

A few commercial kits partially address the detection of these SC-2 variants, but they target general mutations, such as N501Y and E484K in the spike protein, and not variant-specific mutations, such as the N protein D3L substitution or the spike protein 242-244 deletion (https://www.seegene.com/assays/rp, http://www.kogene.co.kr/eng/sub/product/covid-19.asp).

The emergence of novel SC-2 variants with increased infectivity and increased resistance to current vaccines may significantly impair global large-scale detection and vaccination efforts (17). Moreover, it has been shown that different variants having some identical mutation in the spike coding sequence still have different infectivity and vaccine resistance characteristics due to their different set of additional mutations [5, 9, Mandelboim M., unpublished data] . As a result, the pressing need to improve detection methods accordingly requires constant adjustments. Such a diagnostic tests should not only detect the presence of the viral RNA with high specificity and sensitivity, but also provide information on variant identity. Additional consideration is the relatively high cost of commercial kits, and the need to perform complex interpretation of the results, to determine the possible sample identity. The execution and analysis of the assay described herein are simple, and relatively inexpensive, compared with current commercial kits. Implementation of molecular assays such as our multiplex qPCR assay will improve SC-2 diagnosis and contribute to the ongoing efforts to contain the COVID-19 pandemic. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

MultiQC: summarize analysis results for multiple tools and samples in a single report

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev

Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7

Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

The authors wish to thank the members of the Israel Central Virology Laboratory for their valuable help in this work.

The authors declare no conflict of interests.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.19.21257439 doi: medRxiv preprint